Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) EBIT Margin (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBIT Margin for 12 consecutive years, with 168.95% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 75001.0% to 168.95% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 226.0% through Dec 2025, up 210823.0% year-over-year, with the annual reading at 226.0% for FY2025, 210823.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 168.95% at ImmunityBio, up from 173.51% in the prior quarter.
  • The five-year high for EBIT Margin was 168.95% in Q4 2025, with the low at 685514.29% in Q1 2022.
  • Average EBIT Margin over 5 years is 99098.61%, with a median of 46212.69% recorded in 2023.
  • The sharpest move saw EBIT Margin tumbled -62345385bps in 2022, then skyrocketed 65451984bps in 2023.
  • Over 5 years, EBIT Margin stood at 20326.67% in 2021, then tumbled by -472bps to 116301.37% in 2022, then surged by 47bps to 61430.94% in 2023, then skyrocketed by 99bps to 918.96% in 2024, then surged by 82bps to 168.95% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 168.95%, 173.51%, and 269.76% for Q4 2025, Q3 2025, and Q2 2025 respectively.